Related Experiment Videos
Drug-induced thrombotic microangiopathy
Anaadriana Zakarija1, Charles Bennett
1Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA.
Seminars in Thrombosis and Hemostasis
|January 3, 2006
Summary
Drug-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome (TTP/HUS) can result from medications like mitomycin-C. Mechanisms involve immune responses or direct endothelial damage, impacting treatment and outcomes.
Area of Science:
- Hematology
- Toxicology
- Pharmacology
Background:
- Drug-associated thrombotic microangiopathy (TMA), including TTP/HUS, is a known complication.
- Commonly implicated drugs include mitomycin-C, cyclosporine, quinine, and ticlopidine.
Purpose of the Study:
- To review the current understanding of drug-associated TMA.
- To cover pathogenesis, clinical/laboratory features, treatment, prognosis, and outcomes.
Main Methods:
- Literature review of drug-associated TMA.
- Synthesis of current knowledge on pathogenesis and clinical aspects.
Main Results:
- Mechanisms may involve immune-mediated ADAMTS13 dysfunction or direct endothelial toxicity.
- Understanding these pathways is crucial for managing drug-induced TMA.
Conclusions:
- Drug-associated TMA requires careful consideration of potential causative agents.
- Effective management hinges on recognizing pathogenesis and tailoring treatment strategies.